Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Sponsor
Junling Li
Study ID
NCT04670913
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Non Squamous NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    A human anti-PD-1 monoclonal antibody
  • Apatinib — DRUG
    A tyrosine kinase inhibitor selectively targeting VEGFR-2

Study Details

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus Apatinib in the treatment of advanced non-squamous NSCLC previously treated with first-line immunotherapy

Key Dates

Start date
Jun 28, 2021
Status verified
Jun 2021
Primary completion
Dec 31, 2021
Completion
Jun 30, 2022

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab plus Apatinib
    Camrelizumab, 200mg, q3w, iv and Apatinib, 250mg, qd, po

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: up to 1 year ]

Central Contacts